Literature DB >> 14561390

Erythropoietin is a multifunctional tissue-protective cytokine.

Serhat Erbayraktar1, Osman Yilmaz, Necati Gökmen, Michael Brines.   

Abstract

Erythropoietin (EPO) was originally identified as a hormone produced by the adult kidney to facilitate optimum delivery of oxygen to tissue beds by adjustment of the circulating erythrocyte mass. The cloning of the EPO gene, subsequent production of recombinant protein, and successful introduction into clinical practice for the treatment of the anemia of renal failure is a triumph of biotechnology. However, molecular biologic studies have established that EPO is a member of the cytokine superfamily, with significant homology to mediators of growth and inflammation. Therefore, it is not surprising that additional biologic functions for this protein have been identified. Results from studies have shown that EPO and its receptor are widely expressed in embryonic and adult tissues, including the central nervous system, gut, kidney, muscle (eg, smooth, skeletal, and heart), uterus, retina, pancreas, gonads, and lung. We review the evidence that EPO and its receptor function as a paracrine/autocrine system to mediate the protection of tissues subjected to metabolic stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561390

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  22 in total

1.  Effects of Human Erythropoietin on Functional Outcome of Patients with Traumatic Cervical Cord Injury; A Pilot Randomized Clinical Trial.

Authors:  Ehsan Ali Alibai; Fahim Baghban; Majid Reza Farrokhi; Navideh Mohebali; Mohammad Hossein Ashraf
Journal:  Bull Emerg Trauma       Date:  2015-07

2.  Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose.

Authors:  Wentao Luo; Liumei Hu; Weiye Li; Guotong Xu; Linxinyu Xu; Conghui Zhang; Fang Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 3.117

3.  Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis.

Authors:  Matthieu Boucher; Stéphanie Pesant; Yong Hong Lei; Natasha Nanton; Patrick Most; Andrea D Eckhart; Walter J Koch; Erhe Gao
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

4.  Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2014-08-06       Impact factor: 5.372

5.  Targeting Neovascularization in Ischemic Retinopathy: Recent Advances.

Authors:  Mohamed Al-Shabrawey; Mohamed Elsherbiny; Julian Nussbaum; Amira Othman; Sylvia Megyerdi; Amany Tawfik
Journal:  Expert Rev Ophthalmol       Date:  2013-06

6.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Authors:  Ensari Guneli; Zahide Cavdar; Huray Islekel; Sulen Sarioglu; Serhat Erbayraktar; Muge Kiray; Selman Sokmen; Osman Yilmaz; Necati Gokmen
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 8.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

Review 9.  Erythropoietin in spinal cord injury.

Authors:  Georgios K Matis; Theodossios A Birbilis
Journal:  Eur Spine J       Date:  2008-11-22       Impact factor: 3.134

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.